Skip to Content

Generic Egrifta Availability

Egrifta is a brand name of tesamorelin, approved by the FDA in the following formulation(s):

EGRIFTA (tesamorelin acetate - powder;subcutaneous)

  • Manufacturer: THERATECHNOLOGIES
    Approval date: November 10, 2010
    Strength(s): EQ 1MG BASE/VIAL [RLD]
  • Manufacturer: THERATECHNOLOGIES
    Approval date: November 29, 2011
    Strength(s): EQ 2MG BASE/VIAL

Has a generic version of Egrifta been approved?

No. There is currently no therapeutically equivalent version of Egrifta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Egrifta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Chimeric fatty body-pro-GRF analogs with increased biological potency
    Patent 5,861,379
    Issued: January 19, 1999
    Inventor(s): Ibea; Michel & Abribat; Thierry & Brazeau; Paul
    Assignee(s): Theratechnologies Inc.
    The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Patent expiration dates:
    • May 26, 2020
      ✓ 
      Patent use: REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
    Patent 7,144,577
    Issued: December 5, 2006
    Inventor(s): Torres; Ramon A.
    Assignee(s): Applied Research Systems ARS
    Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.
    Patent expiration dates:
    • July 14, 2020
      ✓ 
      Patent use: REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
  • GH secretagogues and uses thereof
    Patent 7,316,997
    Issued: January 8, 2008
    Inventor(s): Abribat; Thierry & De Villers; Andre & Allas; Soraya & Gravel; Denis & Chapdelaine; Alcide
    Assignee(s): Theratechnologies Inc.
    The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Patent expiration dates:
    • August 14, 2023
      ✓ 
      Patent use: REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • November 10, 2015 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide